StockData

Kymera Therapeutics vs Protalix BioTherapeutics

KYMR and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KYMR and PLX compare

Kymera Therapeutics is the larger company, worth 45 times as much as Protalix BioTherapeutics ($10.4B against $232M).

Kymera Therapeutics grew revenue faster over the last twelve months (134% versus 30.1% for Protalix BioTherapeutics).

Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −342% at Kymera Therapeutics.

Protalix BioTherapeutics scores higher on the StockData Score (16 against 9 for Kymera Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKYMRPLX
Size and price
Market cap$10.4B$232M
Share price$121.52$2.88
Change, 1 year87.1%54.8%
Change, 5 years126%191%
Beta (5Y)0.591.40
Employees238226
StockData Score
Total score916 (better)
Valuation score04 (better)
Growth score12 (better)
Performance score24 (better)
Health score66
Dividend score00
Valuation
P/E–12.5×
P/S101×2.9× (better)
P/B6.4×3.2× (better)
EV/EBITDA–8.8×
P/FCF–30.3×
FCF yield−2.8%3.3% (better)
Fair value$37.15$5.38
Margin of safety−227%46.5% (better)
Growth
Revenue growth (TTM)134% (better)30.1%
Revenue growth, 5Y average2.9% (better)−3.5%
Net income growth (TTM)–202%
EPS growth (TTM)–475%
Profitability
Gross margin0.00%69.2% (better)
Operating margin−396%28.9% (better)
Net margin−342%23.5% (better)
FCF margin−283%9.5% (better)
Return on equity−27.3%31.2% (better)
Return on invested capital−59.0%49.5% (better)
Financial health
Debt / equity0.000.00
Current ratio11.13 (better)2.94
Altman Z-score39.62 (better)5.67
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions114%17.9%
Held by insiders38.3%3.8%
Insider net buying, 12 months−$301M$101K (better)
Short interest, % of float16.0%4.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.